Article
Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib in RAS-mutant relapsed or refractory myeloid malignancies.
Cancer - 15 Jun 2016
Borthakur Gautam, Popplewell Leslie, Boyiadzis Michael, Foran James, Platzbecker Uwe, Vey Norbert, Walter Roland B, Olin Rebecca, Raza Azra, Giagounidis Aristoteles, Al-Kali Aref, Jabbour Elias, Kadia Tapan, Garcia-Manero Guillermo, Bauman John W, Wu Yuehui, Liu Yuan, Schramek Dan, Cox Donna S, Wissel Paul, Kantarjian Hagop
Abstract excerpt
BACKGROUND: RAS/RAF/mitogen-activated protein kinase activation is common in myeloid malignancies. Trametinib, a mitogen-activated protein kinase kinase 1 (MEK1)/MEK2 inhibitor with activity against multiple myeloid cell lines at low nanomolar concentrations, was evaluated for safety and clinical activity in patients with relapsed/refractory leukemias. METHODS: This phase 1/2 study accrued patients with any...
Topics
- Adult
- Aged
- Aged, 80 and over
- Dose-Response Relationship, Drug
- Humans
- Kaplan-Meier Estimate
- Leukemia
- Leukemia, Myeloid, Acute
- MAP Kinase Signaling System